Eylea (aflibercept) Injection is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) which is a major cause of blindness in older adults.
The injection secured approval from the Food and Drug Administration (FDA) on 18 November 2011.
Express Scripts business development senior director Rob Osborne said the number of people affected by macular degeneration is increasing due to rise in aging population.
"HealthBridge Pharma & Biotech is proud to provide services that will help patients get the medication they need to treat this debilitating disease," Osborne added.